PMID- 36018231
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20221207
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Linking)
VI  - 42
IP  - 5
DP  - 2022 Sep-Oct 01
TI  - Effects of Selective Serotonin Reuptake Inhibitor Use on 
      3,4-Methylenedioxymethamphetamine-Assisted Therapy for Posttraumatic Stress 
      Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical 
      Significance.
PG  - 464-469
LID - 10.1097/JCP.0000000000001595 [doi]
AB  - BACKGROUND: Among the renewed applications of psychedelic medicines in 
      psychiatry, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for 
      posttraumatic stress disorder (PTSD) has demonstrated the most promise in early 
      small-scale studies. Recent exploratory analyses from prior clinical trials of 
      MDMA-assisted therapy for PTSD have suggested that recent use of selective 
      serotonin reuptake inhibitors (SSRIs)-the only medication class with United 
      States Food and Drug Administration (FDA) approval to treat PTSD-can 
      significantly dampen the efficacy of this novel therapy. Although psychedelic 
      medicines are not yet FDA approved, MDMA is very likely to be the first to 
      achieve FDA approval-perhaps within the next 2 years. Given this timeline, the 
      field would benefit from more knowledge about potential interactions between this 
      novel therapy and our current treatments. METHODS: This brief report reviews 
      selected literature in the basic and clinical neurosciences relevant to the 
      interaction of SSRIs and MDMA. FINDINGS: The possibility that SSRI use could 
      dampen future responses to MDMA-assisted therapy for PTSD raises many important 
      questions about the biological mechanisms as well as ethical implications around 
      the most appropriate way to counsel patients. In this brief report, we compare 
      the evidence for SSRIs and MDMA-assisted therapy in the treatment of PTSD and 
      discuss what is known about the neurobiological interactions between these 2 
      medicines. CONCLUSIONS: There is strong neurobiological plausibility for the 
      hypothesis that chronic SSRI use dampens response to MDMA-assisted therapy, 
      although current knowledge in the field is limited and primarily relates to acute 
      pharmacodynamic interactions. Our commentary highlights the urgent need for 
      future work dedicated to addressing this important clinical topic.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Price, Collin M
AU  - Price CM
AD  - From the Department of Psychiatry, UCLA Semel Institute for Neuroscience and 
      Human Behavior, University of California Los Angeles.
FAU - Feduccia, Allison A
AU  - Feduccia AA
AD  - Psychedelic Support, Santa Cruz, CA.
FAU - DeBonis, Katrina
AU  - DeBonis K
AD  - From the Department of Psychiatry, UCLA Semel Institute for Neuroscience and 
      Human Behavior, University of California Los Angeles.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220820
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *Hallucinogens
MH  - Humans
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
MH  - Psychotherapy
MH  - Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use
MH  - *Stress Disorders, Post-Traumatic/drug therapy
EDAT- 2022/08/27 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/08/26 09:52
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2022/08/26 09:52 [entrez]
AID - 00004714-990000000-00046 [pii]
AID - 10.1097/JCP.0000000000001595 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5):464-469. doi: 
      10.1097/JCP.0000000000001595. Epub 2022 Aug 20.